Authors
Latest:
Industry Predictions For 2023Top industry experts weigh in on what the new year holds for the pharma industry.
Latest:
Maximizing China Access for Innovative TherapiesTo maximize the potential of innovative therapies in the Chinese market, it’s important to have a holistic view of the full range of options and levers, prioritize and sequence the ones with the highest impacts, and develop an integrated strategy tailored to address the country’s unmet needs.
Latest:
Positioning Medical Information as a Trust Driver for Your BrandFour steps to maximize the impact of medical information services as an engagement gateway.
Latest:
Despite Slowing Economy, Demand for Pharma Talent RisesPharma companies need to rethink their strategies to ensure that they hire the best available talent in today's market.
Latest:
Almirall’s Garden of InnovationClay Hausmann describes how Almirall is weeding out uncertainty to sow the seeds of data-driven digital transformation.
Latest:
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative ColitisJohnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Latest:
How Pharma Reps and Managers Can Work to Overcome the In-Person HCP BarrierWhile HCPs are turning away from in-person meetings with sales reps amidst the COVID-19 pandemic, there are still strategies for them to keep their pipelines full.
Latest:
Overcoming Hidden Obstacles in the Script-to-Therapy JourneyBy integrating support directly into existing workflows and focusing on solutions that eliminate "shoulder time," manufacturers can significantly reduce delays and improve patient outcomes.
Latest:
Market Access And Treatment OutcomesShifting from the volume of data to the value of insights
Latest:
Lessons Learned Working with Millions of Patients on Specialty MedicationsAdditional assistance necessary for patients prescribed specialty therapies.
Latest:
Addressing Health Disparities Through Robust Patient Support ProgramsIdentifying unique traits in patients is key to creating the most effective support programs.
Latest:
How Cloud-Based Business Management Can Streamline Processes, Manage Reporting Better, and Create Stronger Financial ControlsThursday June 8, 2022 at 11am PDT | 2pm EDT | 7pm BST | 8pm CEST Learn how life sciences companies can navigate growth by leveraging NetSuite for streamlined processes, better management reporting, and stronger financial controls to ensure real-time management decision-making and regulatory compliance.
Latest:
Prospective Measures to Combat Rising Drug Prices in GermanyThis article provides an overview of potential tools being explored in Germany by Health Insurance Funds to better control drug prices and healthcare spend, offering insight into which measure may be implemented.
Latest:
Dynamic Compliance: The Best Defense for PharmaA proactive and tailored compliance department—with the nimbleness to adapt strategies on the fly—is a critical shield for life sciences companies during government investigations.
Latest:
The Biopharma SME Revolution: Opportunities & Challenges Post-COVIDAhmed Bouzidi explores the opportunities and challenges facing small and mid-size biopharma companies as they strive to bring their latest innovations to market.
Latest:
Taking Steps Toward a Sustainable FutureStrategies to become a Certified B Corporation, and the benefits to the industry, its stakeholders, and the world.
Latest:
How Medical Affairs Can Contribute to Successful Drug LaunchFaster launch planning leads to greater access.
Latest:
Three Steps to Revitalizing the Life Sciences Industry with AI-Enabled TechnologiesMeeting demands of the new marketplace.
Latest:
COVID-19: Therapeutics Under InvestigationJanita Good looks at some of the therapeutics currently under investigation and the issues they have highlighted in the context of a pandemic.
Latest:
The Importance of Responsible and Transparent Communications in Pharma MarketingPharma marketing strategies that are both socially and ethically responsible can build long term success for the life sciences industry.
Latest:
Payers Believe Lowering Drug Prices While Improving Patient Access Is Possible—but There’s a CatchValue-based price for access (VBPA) may increase access of specialty drugs for patients.
Latest:
Are You Ready for the Telemedicine Revolution?A new patient journey is emerging. Gilda Sala, Trista Bridges, and Rune Soelvsteen offer easy steps to future-proof your company’s approach.
Latest:
Reducing Prescription Drug Costs for Seniors: The ABCs of ASP for Part DOutlining the steps to a payment approach for Medicare Part D drugs that provides savings for patients.
Latest:
Gross-to-Net is not just a process but a way for business growthDefining what Gross-to-Net mean and why it is important to Life Sciences companies; Identify who in the company benefits in utilizing information from GTN; Get insights to successfully define and manage GTN process
Latest:
In life sciences, the metaverse opportunity knocksHere are three mindsets for pharma companies to adopt now to reap the rewards of early action in the metaverse.
Latest:
Thriving ‘Beyond the Pill’: Closing Key Gap in Patient SupportWhy pharma needs to focus on improving—not just extending life.
Latest:
The Three Core Ingredients of Lasting Patient EngagementBiopharma marketers use experience to grow brands into fixtures in patient discourse
Latest:
Challenges of Patient Engagement in Atopic DermatitisHannah Brown & Elizabeth Baynton explore the atopic dermatitis patient-doctor dynamic and identify opportunities to optimize patient outcomes.
Latest:
Prospective Measures to Combat Rising Drug Prices in GermanyThis article provides an overview of potential tools being explored in Germany by Health Insurance Funds to better control drug prices and healthcare spend, offering insight into which measure may be implemented.
